Airrosti's REACH Platform Aims to Redefine Digital MSK Care

SAN ANTONIO, TX – February 06, 2026 – Airrosti, a national provider of musculoskeletal (MSK) care, today launched REACH, a new platform that combines digital access with its long-standing clinical model in an ambitious bid to address the shortcomings of the current digital health market. The move aims to tackle the more than $350 billion spent annually on MSK conditions by offering employers and health plans a solution that promises not just user engagement, but concrete clinical outcomes and significant cost savings.

The new platform, REACH, integrates virtual triage, digitally-guided and in-person treatment, and preventative care into a single system. It represents a significant strategic shift, extending Airrosti’s treatment methodology, which has been refined over two decades and nearly two million patient cases, to a national audience for the first time.

"This is a clinical reinvention, not a digital feature release," said Chris Cato, D.C., Founding Clinician and Chief Population Health Officer at Airrosti. "For the first time, we've translated our myofascial release–based treatment approach into a scalable digital platform without losing the clinical rigor that made it effective."

Beyond the App: A Clinical Model Goes Digital

Unlike many first-generation digital MSK solutions that rely heavily on generic exercise videos and content, Airrosti's REACH is built around a distinct clinical framework. For over 20 years, the company has centered its care on a combination of hands-on myofascial release—a manual therapy targeting muscle and connective tissue—and specific, active rehabilitation. The goal has always been rapid pain resolution and restoration of function.

REACH deconstructs this model into a three-part digital-to-physical ecosystem:

• REACH A Doc: Provides members with immediate virtual access to a licensed Airrosti provider for initial assessment, triage, and guidance on the appropriate care pathway.
• REACH Rapid Relief: Delivers the core treatment. This can be a virtual session where providers guide patients through self-myofascial release techniques or a seamless referral to one of Airrosti’s in-person providers for hands-on care.
• REACH Better Movement: A preventative component that offers digital programs for self-management and injury prevention, translating the company's clinical insights into long-term wellness strategies.

This integrated approach is designed to move beyond the "engagement without outcomes" problem that has caused digital MSK care to plateau. By anchoring the platform in clinical diagnosis and appropriate care escalation, Airrosti aims to provide a more precise and effective alternative to one-size-fits-all app-based programs.

The $350 Billion Problem and a Promise of Savings

The launch of REACH is supported by compelling financial data aimed squarely at employers and health plans struggling with soaring MSK-related costs. Musculoskeletal pain is a leading driver of medical spend, absenteeism, and disability claims.

Airrosti is highlighting a recent claims-based study completed on December 10, 2025. The analysis compared MSK patients treated by Airrosti to a matched group who received care from other provider types. The results showed that Airrosti patients cost significantly less, with an average savings of $2,329 per member per year (PMPY) on direct MSK costs and an even more substantial $3,607 PMPY in savings on total medical spend.

"Airrosti has long maintained that by getting patients healthy quickly, there would be additional benefits for employers," said Mark Metcalfe, CEO of Airrosti. "Not only would there be less absenteeism as employees need less time for treatment, but employers would see significant savings on their medical spend. This study confirms that both MSK costs and overall medical costs are significantly less for Airrosti patients."

This latest study builds on a decade of the company’s data-driven validation. An earlier cost study conducted by the independent firm Milliman helped establish Airrosti's reputation for delivering quantifiable results, and the company continues to leverage claims analysis to prove its model's efficiency.

Navigating a Crowded Digital Health Market

Airrosti enters a competitive digital MSK landscape where well-funded players like Hinge Health and Sword Health have already gained significant traction. These companies also present strong ROI cases to employers. For instance, Hinge Health has published data showing medical claims savings of over $2,300 per participant, while Sword Health reports savings of more than $3,100 per member and a significant reduction in lost workdays.

However, Airrosti is betting that its unique clinical foundation will be a key differentiator. While competitors largely focus on virtual physical therapy, exercise programs, and health coaching, REACH is explicitly grounded in the company's proprietary myofascial release methodology. The platform is not just about making exercise more accessible; it's about scaling a specific, proven treatment that has traditionally been delivered in person. This focus on "clinically accountable care" is a direct challenge to what Airrosti calls "low-impact, exercise-only digital solutions."

The Science and Scalability of Myofascial Release

The clinical core of Airrosti's model, myofascial release (MFR), is a manual therapy technique used by physical therapists, chiropractors, and other licensed professionals to treat skeletal muscle immobility and pain by relaxing contracted muscles, improving circulation, and stimulating the stretch reflex. Research has shown MFR can be effective in improving pain and physical function for conditions like chronic low back pain and fibromyalgia.

While the technique is widely used and accepted in clinical practice, some academic reviews note that the body of high-quality research is still developing, calling for more large-scale, randomized controlled trials to further solidify the evidence base. The primary challenge has always been its reliance on a trained, hands-on practitioner.

The innovation of REACH lies in its attempt to solve this scalability problem. By creating a system that can virtually guide patients in self-application of these principles or efficiently direct them to a network provider for manual intervention, Airrosti is democratizing access to its specialized care. This hybrid model allows the company to maintain its clinical rigor while breaking down the geographical barriers that have historically limited its reach, making its outcome-based approach available to patients and employers across all 50 states.